Huntington National Bank Has $42.37 Million Holdings in Eli Lilly and Company (NYSE:LLY)


Share on StockTwits

Huntington National Bank grew its position in Eli Lilly and Company (NYSE:LLY) by 4.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 226,795 shares of the company’s stock after purchasing an additional 9,817 shares during the quarter. Huntington National Bank’s holdings in Eli Lilly and were worth $42,370,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in LLY. Perennial Advisors LLC bought a new position in Eli Lilly and during the 4th quarter worth $31,000. DB Wealth Management Group LLC acquired a new position in shares of Eli Lilly and in the fourth quarter valued at about $34,000. Retirement Group LLC bought a new position in Eli Lilly and during the fourth quarter worth about $33,000. Archer Investment Corp raised its stake in Eli Lilly and by 83.3% in the 4th quarter. Archer Investment Corp now owns 220 shares of the company’s stock worth $37,000 after purchasing an additional 100 shares in the last quarter. Finally, Accel Wealth Management acquired a new stake in shares of Eli Lilly and in the fourth quarter valued at approximately $37,000. Institutional investors own 75.59% of the company’s stock.

Shares of NYSE:LLY traded down $2.74 during trading on Monday, reaching $181.75. The stock had a trading volume of 13,421 shares, compared to its average volume of 4,255,209. Eli Lilly and Company has a 52 week low of $129.21 and a 52 week high of $218.00. The company has a debt-to-equity ratio of 3.27, a quick ratio of 1.06 and a current ratio of 1.36. The firm’s fifty day moving average is $194.73 and its 200 day moving average is $171.69. The stock has a market cap of $174.30 billion, a price-to-earnings ratio of 30.15, a P/E/G ratio of 1.57 and a beta of 0.37.

Eli Lilly and (NYSE:LLY) last released its earnings results on Thursday, January 28th. The company reported $2.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.35 by $0.40. Eli Lilly and had a net margin of 24.01% and a return on equity of 166.45%. The business had revenue of $7.44 billion for the quarter, compared to analyst estimates of $7.27 billion. During the same quarter in the previous year, the business earned $1.73 earnings per share. Eli Lilly and’s revenue for the quarter was up 21.7% on a year-over-year basis. On average, research analysts forecast that Eli Lilly and Company will post 7.56 earnings per share for the current fiscal year.

In related news, major shareholder Lilly Endowment Inc sold 125,284 shares of the company’s stock in a transaction dated Monday, March 8th. The stock was sold at an average price of $209.69, for a total transaction of $26,270,801.96. Following the sale, the insider now owns 110,422,933 shares in the company, valued at approximately $23,154,584,820.77. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.09% of the stock is owned by insiders.

A number of equities analysts have recently commented on the company. Mizuho boosted their price target on Eli Lilly and from $222.00 to $228.00 and gave the stock a “buy” rating in a report on Monday, February 1st. Morgan Stanley increased their target price on Eli Lilly and from $190.00 to $217.00 and gave the company an “overweight” rating in a research report on Thursday, February 4th. Truist Securities boosted their price target on Eli Lilly and from $215.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, March 22nd. Bank of America upped their price objective on Eli Lilly and from $195.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, January 22nd. Finally, Truist lifted their target price on shares of Eli Lilly and from $200.00 to $215.00 in a research report on Monday, February 1st. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $193.88.

About Eli Lilly and

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading: Equal Weight Rating

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.